Traditional Chinese medicine composition, preparation and application thereof

Through the effects of warming yang and replenishing qi, relieving lungs and relieving asthma, relieving phlegm and removing dampness, the problem of bronchial asthma treatment in the prior art cannot reduce the frequency of attack and poor compliance with long-term medication, significantly improve asthma symptoms and quality of life, and have relatively good results. Good treatment effect.

CN119015381APending Publication Date: 2024-11-26YANGTZE RIVER PHARMA GRP JIA NGSU LONGFENGTANG TRADITIONAL CHINESE MEDICINE CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310595378.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-24
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing bronchial asthma treatment methods can only relieve the symptoms of acute attacks, cannot effectively reduce the frequency of asthma attacks, and have poor long-term medication compliance, making it difficult to ensure disease control and lung function protection.

Method used

A Chinese medicine composition is adopted, including ephedra, Morinica, Astragalus, Atractylodes, Dried Ginger, Asarum, Schisandra chinensis, Ejaculation, Wind-proof, and Licorice. It is used as the bronchial system by warming yang and replenishing qi, relieving lungs and relieving asthma, relieving phlegm and removing dampness. Treatment of asthma.

Benefits of technology

Significantly improve the symptoms of wheezing, rushing breath, chest tightness, sputum, etc. in asthma patients, reduce the symptoms of fatigue and dampness, improve the quality of life, reduce the frequency of asthma attacks, have good efficacy, and reduce hormone use and adverse reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015381A_ABST
    Figure CN119015381A_ABST
Patent Text Reader

Abstract

The invention relates to a traditional Chinese medicine composition, a preparation and application thereof. The traditional Chinese medicine composition can be used as a medicine for treating bronchial asthma in an acute attack period and a chronic duration period. The traditional Chinese medicine composition comprises the following raw materials: ephedra, morinda officinalis, astragalus membranaceus, rhizoma atractylodis, rhizoma zingiberis, asarum, schisandra chinensis, pinellia ternate, blackberry lily, divaricate saposhnikovia root and liquorice.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition, a preparation and application thereof. Background Art

[0002] Bronchial asthma is a heterogeneous disease characterized by chronic airway inflammation, with clinical manifestations of recurrent wheezing and shortness of breath, with or without chest tightness or cough, accompanied by airway hyperresponsiveness and variable airflow limitation, which may lead to changes in airway structure as the disease progresses. Traditional Chinese medicine believes that the pathogenesis of bronchial asthma is mainly lung and kidney qi deficiency and internal obstruction of phlegm. Modern medicine believes that bronchial asthma is a chronic airway inflammatory disease involving multiple cells and cell components. The goal of treatment is to achieve good control of asthma symptoms and maintain normal activity levels, while minimizing the risk of acute attacks and death, irreversible damage to lung function, and drug-related adverse reactions.

[0003] In the treatment of bronchial asthma, modern medicine prefers glucocorticoids and β2 receptor agonists to inhibit airway inflammation, relieve airflow limitation, improve hypoxemia, and alleviate clinical symptoms. However, most treatments can only relieve the symptoms of acute asthma attacks and cannot fundamentally reduce the frequency of asthma attacks. In addition, long-term medication compliance is difficult to ensure.

[0004] To this end, the present invention is proposed. Summary of the invention

[0005] The object of the present invention is to provide a Chinese medicine composition, a preparation and application thereof, wherein the Chinese medicine composition can be used as a therapeutic medicine for the acute attack stage and the chronic persistent stage of bronchial asthma.

[0006] To achieve the above object, the technical solution adopted by the present invention is:

[0007] The first aspect of the present invention provides a traditional Chinese medicine composition, which comprises the following raw materials: ephedra, Morinda officinalis, astragalus, atractylodes, dried ginger, asarum, schisandra, pinellia, belamcanda, siler, and liquorice.

[0008] In one embodiment, the traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 6-12 parts of ephedra, 7-13 parts of Morinda officinalis, 27-33 parts of astragalus, 7-13 parts of atractylodes, 5-11 parts of dried ginger, 1-7 parts of asarum, 5-11 parts of schisandra, 7-13 parts of pinellia, 9-15 parts of belamcanda, 7-13 parts of siler, and 2-8 parts of licorice.

[0009] The above-mentioned Chinese medicine composition is based on the clinical characteristics of repeated attacks of cough and asthma in asthma patients, which are often accompanied by fear of cold, susceptibility and allergy. It is proposed that the pathogenesis of asthma is qi yang deficiency as the root, and wind cold dampness depression as the mark. Qi yang deficiency, the defense outside is not solid, then fear of cold and susceptibility. Exogenous wind and cold, evil accumulates in the lungs, qi does not distribute fluid, transforms into phlegm and dampness, causing wind cold dampness depression. Wetness is heavy and turbid, and it stays in the viscera and meridians, which is most likely to block the qi mechanism, causing the qi mechanism to rise and fall abnormally, and the airway is blocked and develops asthma. Dampness is a problem, and the symptoms are mostly sticky and uncomfortable, and the condition is lingering and difficult to cure, so asthma is a disease, and the course of disease is long and easy to recur. Treatment should be based on warming yang and replenishing qi, ventilating the lungs and relieving asthma, and resolving phlegm and removing dampness. This prescription uses ephedra, astragalus, and Morinda officinalis as the main medicine to open the lung qi, replenish qi and raise yang, and warm the kidney and remove dampness. The assistant drugs, dried ginger and asarum, warm the lungs and dispel cold, Atractylodes lancea dries dampness and strengthens the spleen, Saposhnikovia divaricata dispels wind and overcomes dampness, and Schisandra chinensis nourishes the lungs and kidneys, and they assist the main drugs to warm the lungs and strengthen the kidneys, strengthen the spleen and eliminate dampness. Belamcanda and Pinellia tuber descend qi and resolve phlegm, relieve cough and asthma, and are adjuvant drugs. Licorice harmonizes the drugs and is the guiding drug. The combination of the drugs treats both the symptoms and the root cause, and has the effects of warming yang and invigorating qi, promoting lung function and relieving asthma, and resolving phlegm and removing dampness.

[0010] In addition, the clinical trial results of the above-mentioned Chinese medicine composition show that after taking the medicine, the symptoms of asthma patients such as wheezing, shortness of breath, chest tightness, expectoration, wheezing, etc. are significantly improved, and the symptoms of dampness such as fatigue, sticky mouth, etc. are alleviated, the quality of life is improved, and lung function can be improved. Studies have shown that the composition has a good effect in treating patients with mild and moderate bronchial asthma, and can be used as a therapeutic drug for the acute attack period and chronic persistent period of bronchial asthma.

[0011] In summary, compared with Western medicine, the Chinese medicine composition provided by the present invention has unique advantages in preventing and controlling asthma attacks by improving the functions of internal organs and regulating the body's overall state. While reducing the use of hormones and adverse reactions, it also achieves good results in the treatment of asthma and other related symptoms, and can improve the quality of life of patients.

[0012] In one embodiment, the traditional Chinese medicine composition includes the following raw materials in parts by weight: 6-9 parts of ephedra, 10-13 parts of Morinda officinalis, 27-30 parts of astragalus, 10-13 parts of atractylodes, 5-8 parts of dried ginger, 4-7 parts of asarum, 5-8 parts of schisandra, 10-13 parts of pinellia, 9-12 parts of belamcanda, 10-13 parts of siler, and 2-5 parts of licorice.

[0013] In one embodiment, the Chinese medicine composition includes the following raw materials in parts by weight: 9 parts of ephedra, 10 parts of Morinda officinalis, 30 parts of astragalus, 10 parts of atractylodes, 8 parts of dried ginger, 4 parts of asarum, 8 parts of schisandra, 10 parts of pinellia, 12 parts of belamcanda, 10 parts of siler, and 5 parts of liquorice.

[0014] In one embodiment, the ephedra in the traditional Chinese medicine composition is preferably honey ephedra, the Morinda officinalis is preferably salt Morinda officinalis, the Schisandra chinensis is preferably steamed Schisandra chinensis, the Pinellia ternata is preferably French Pinellia ternata, and the Licorice is preferably roasted Licorice.

[0015] The second aspect of the present invention provides a preparation of the above-mentioned Chinese medicine composition, which is an oral preparation, such as tablets, capsules, mixtures, pills, oral liquids, granules, syrups, pellets, elixirs, suspensions, emulsions, extracts, etc.

[0016] In addition to the above-mentioned preparations, the Chinese medicine composition of the present invention can also be made into inhalants such as aerosols, solutions and dry powders.

[0017] In one embodiment, the dosage form of the traditional Chinese medicine composition is an oral preparation, which includes syrups, extracts, tablets, mixtures, capsules, granules, and oral liquids.

[0018] The above dosage forms are all commonly used dosage forms of Chinese patent medicines, and can be prepared by adding appropriate amounts of pharmaceutically acceptable excipients based on the above Chinese medicine composition according to conventional methods in the art.

[0019] The third aspect of the present invention provides use of the Chinese medicine composition of the first aspect or the preparation of the second aspect in the preparation of a drug for inhibiting bronchial smooth muscle contraction.

[0020] In one embodiment, the above-mentioned Chinese medicine composition and preparation are used in the preparation of drugs for treating bronchial asthma.

[0021] In one embodiment, the above-mentioned Chinese medicine composition and preparation can be used to prepare a drug for treating bronchial asthma of Qi deficiency and dampness obstruction type.

[0022] Beneficial effects:

[0023] 1. This application prescription uses Ephedra, Astragalus, and Morinda officinalis as the main drugs to promote the lung qi, replenish qi and raise yang, warm the kidney and remove dampness. The assistant drugs, dried ginger and asarum, warm the lung and dispel cold, Atractylodes lancea, dry dampness and strengthen the spleen, Saposhnikovia divaricata, and Schisandra chinensis, jointly assist the main drugs to warm the lung and strengthen the kidney, strengthen the spleen and remove dampness. Belamcanda and Pinellia tuber descend qi and resolve phlegm, relieve cough and relieve asthma, and are adjuvant drugs. Licorice harmonizes all the drugs and is the guiding drug. The whole prescription plays the role of warming yang and replenishing qi, promoting lung and relieving asthma, and resolving phlegm and removing dampness.

[0024] 2. Pharmacological results show that the prescription of this application exerts its efficacy through the mechanism of inhibiting the contraction of bronchial smooth muscle, and the relationship is dose-effect.

[0025] 3. Clinical trial results show that after taking the medicine, asthma patients' symptoms such as wheezing, shortness of breath, chest tightness, expectoration, wheezing, etc. are significantly improved, and the symptoms of dampness such as fatigue, sticky mouth, etc. are effectively relieved. It can also improve lung function, significantly reduce the frequency of asthma attacks, and improve the quality of life. Studies have shown that the drugs in the prescription have good clinical efficacy in the treatment of mild and moderate bronchial asthma patients, and can be used as a treatment for acute attacks and chronic persistent stages of bronchial asthma.

[0026] The above description is only an overview of the technical solution of the present application. In order to more clearly understand the technical means of the present application, it can be implemented in accordance with the contents of the specification. In order to make the above and other purposes, features and advantages of the present application more obvious and easy to understand, the specific implementation methods of the present application are listed below. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Various other advantages and benefits will become apparent to those of ordinary skill in the art by reading the detailed description of the preferred embodiments below. The accompanying drawings are only for the purpose of illustrating the preferred embodiments and are not to be considered as limiting the present application. Moreover, the same reference numerals are used throughout the drawings to represent the same components. In the drawings:

[0028] Figure 1 and Figure 2 To alleviate the dose-effect relationship of acetylcholine-induced smooth muscle contraction in mice;

[0029] Figure 3 and Figure 4 To alleviate the dose-effect relationship of high potassium concentration-induced smooth muscle contraction in mice;

[0030] Figure 5 Asthma Control Test Form;

[0031] Figure 6 and 7 Asthma Quality of Life Questionnaire;

[0032] Figure 8 and 9 Asthma Control Questionnaire;

[0033] Fig.10 The Asthma Control Assessment Questionnaire for Adults;

[0034] Fig.11 It is a scale for assessing dampness syndrome in traditional Chinese medicine. DETAILED DESCRIPTION

[0035] The following embodiments of the technical solution of the present application are described in detail in conjunction with the accompanying drawings. The following embodiments are only used to more clearly illustrate the technical solution of the present application, and are therefore only used as examples, and cannot be used to limit the scope of protection of the present application.

[0036] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by technicians in the technical field to which this application belongs; the terms used herein are only for the purpose of describing specific embodiments and are not intended to limit this application; the terms "including" and "having" in the specification and claims of this application and the above-mentioned figure descriptions and any variations thereof are intended to cover non-exclusive inclusions.

[0037] Reference to "embodiments" herein means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present application. The appearance of the phrase in various locations in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein may be combined with other embodiments.

[0038] In the description of the embodiments of the present application, the term "and / or" is only a description of the association relationship of the associated objects, indicating that there may be three relationships. For example, A and / or B can represent: A exists alone, A and B exist at the same time, and B exists alone. In addition, the character " / " in this article generally indicates that the associated objects before and after are in an "or" relationship.

[0039] In the description of the embodiments of the present application, the term "multiple" refers to more than two (including two). Similarly, "multiple groups" refers to more than two groups (including two groups), and "multiple pieces" refers to more than two pieces (including two pieces).

[0040] The present invention will be further described below in conjunction with the embodiments.

[0041] Example 1

[0042] A traditional Chinese medicine composition, which is composed of the following raw materials in parts by weight: 9 parts of honey ephedra, 10 parts of salt Morinda officinalis, 30 parts of astragalus, 10 parts of atractylodes, 8 parts of dried ginger, 4 parts of asarum, 8 parts of steamed schisandra, 10 parts of French pinellia, 12 parts of belamcanda, 10 parts of siler, and 5 parts of roasted liquorice. Each medicinal material is weighed according to a proportion, water is added for decoction, and a decoction is obtained, which is concentrated to obtain the decoction.

[0043] Example 2

[0044] A traditional Chinese medicine composition, which is composed of the following raw materials in parts by weight: 9 parts of ephedra, 10 parts of Morinda officinalis, 30 parts of astragalus, 10 parts of atractylodes, 8 parts of dried ginger, 4 parts of asarum, 8 parts of schisandra, 10 parts of pinellia, 12 parts of belamcanda, 10 parts of siler, and 5 parts of liquorice. Each medicinal material is weighed according to proportion, water is added and boiled to obtain a decoction, which is concentrated to obtain the decoction.

[0045] Example 3

[0046] A traditional Chinese medicine composition, which is composed of the following raw materials in parts by weight: 6 parts of honey ephedra, 7 parts of salt Morinda officinalis, 27 parts of astragalus, 7 parts of atractylodes, 5 parts of dried ginger, 1 part of asarum, 5 parts of steamed schisandra, 7 parts of French pinellia, 9 parts of belamcanda, 7 parts of siler, and 2 parts of roasted liquorice. Each medicinal material is weighed according to a proportion, and water is added for decoction to obtain a decoction, which is concentrated to obtain the decoction.

[0047] Example 4

[0048] A traditional Chinese medicine composition, which is composed of the following raw materials in parts by weight: 6 parts of ephedra, 7 parts of Morinda officinalis, 27 parts of astragalus, 7 parts of atractylodes, 5 parts of dried ginger, 1 part of asarum, 5 parts of schisandra, 7 parts of pinellia, 9 parts of belamcanda, 7 parts of siler, and 2 parts of liquorice. The medicinal materials are weighed according to proportion, water is added and boiled to obtain a decoction, which is concentrated to obtain the decoction.

[0049] Example 5

[0050] A traditional Chinese medicine composition, which is composed of the following raw materials in parts by weight: 12 parts of honey ephedra, 13 parts of salt Morinda officinalis, 33 parts of astragalus, 13 parts of atractylodes, 11 parts of dried ginger, 7 parts of asarum, 11 parts of schisandra, 13 parts of pinellia, 15 parts of belamcanda, 13 parts of siler, and 8 parts of roasted liquorice. Each medicinal material is weighed according to proportion, water is added for decoction, and a decoction is obtained, which is concentrated to obtain the decoction.

[0051] Example 6

[0052] A traditional Chinese medicine composition, which is composed of the following raw materials in parts by weight: 12 parts of ephedra, 13 parts of Morinda officinalis, 33 parts of astragalus, 13 parts of atractylodes, 11 parts of dried ginger, 7 parts of asarum, 11 parts of schisandra, 13 parts of pinellia, 15 parts of belamcanda, 13 parts of siler, and 8 parts of liquorice. Each medicinal material is weighed according to a proportion, water is added and boiled to obtain a decoction, which is concentrated to obtain the decoction.

[0053] Example 7

[0054] A traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 9 parts of ephedra, 10 parts of Morinda officinalis, 30 parts of astragalus, 10 parts of atractylodes, 8 parts of dried ginger, 4 parts of asarum, 8 parts of schisandra, 10 parts of pinellia, 12 parts of belamcanda, 10 parts of siler, and 5 parts of liquorice. The medicinal materials are weighed according to proportion, boiled with water to obtain a decoction, concentrated, added with pharmaceutically acceptable excipients, dried, crushed and granulated, and pressed into tablets or filled into capsules.

[0055] Example 8

[0056] A traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 9 parts of ephedra, 10 parts of Morinda officinalis, 30 parts of astragalus, 10 parts of atractylodes, 8 parts of dried ginger, 4 parts of asarum, 8 parts of schisandra, 10 parts of pinellia, 12 parts of belamcanda, 10 parts of siler, and 5 parts of liquorice. The medicinal materials are weighed according to proportion, boiled with water to obtain a decoction, concentrated and dried, and pharmaceutically acceptable excipients are added, granulated, and dried to prepare granules.

[0057] Example 9

[0058] A traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 9 parts of ephedra, 10 parts of Morinda officinalis, 30 parts of astragalus, 10 parts of atractylodes, 8 parts of dried ginger, 4 parts of asarum, 8 parts of schisandra chinensis, 10 parts of pinellia, 12 parts of belamcanda, 10 parts of siler, and 5 parts of liquorice. The medicinal materials are weighed according to proportion, boiled with water to obtain a decoction, which is concentrated, and pharmaceutically acceptable excipients are added to prepare a mixture, an oral liquid or a syrup.

[0059] Test Example 1

[0060] Effect of the drug of the present invention on contraction of isolated mouse tracheal smooth muscle

[0061] (1) Experimental Materials

[0062] ① Animals: All were male SD mice, weighing (18-22) g.

[0063] ②Drugs and reagents:

[0064] Take the Chinese medicine composition of Example 1 above and add water to prepare a Chinese medicine extract of 1-40 mg / mL.

[0065] PSS buffer, adjust pH to 7.4.

[0066] (2) Experimental methods

[0067] ① After killing the mouse by euthanasia, the trachea was quickly separated, the surrounding adherent connective tissue was cut off, and a tracheal ring about 5 mm long was taken from the proximal triangle area and transferred to pre-cooled PSS buffer for storage.

[0068] ② The prepared tracheal rings were suspended in a constant temperature oxygenated isolated tissue perfusion system containing 10 mL of 37°C PSS buffer. Before the experiment, the tracheal rings were given an appropriate preload until the tension of the isolated tracheal smooth muscle (ASM) reached a stable state (about 60 minutes), and the tension was recorded. Then 100 μM acetylcholine (ACh) was used to stimulate contraction, so that the tracheal rings reached the optimal contraction state; the tracheal rings were washed with PSS buffer and re-equilibrated for 30 minutes before the formal experiment.

[0069] ③ Treat with 100μM ACh or 60mM KCl, observe the reaction of tracheal rings, and record the change of ASM tension (the maximum tension value is F0); after ASM reaches the maximum tension, add 1, 2, 5, 10, 20, 30, and 40mg / mL of Chinese herbal extract in sequence, with an interval of 10 minutes between each addition. Soak and administer the drugs, observe the reaction of tracheal rings, and record the change of ASM tension (the stable tension value after addition is F).

[0070] ④ Wash the tracheal rings with PSS buffer and re-equilibrate, then repeat step ③.

[0071] ⑤The smooth muscle relaxation value is calculated according to the following formula:

[0072]

[0073] ⑥ Draw a curve with the logarithm of drug concentration as the horizontal axis and the smooth muscle relaxation value as the vertical axis to establish the concentration response curve of ACh and KCl to ASM contraction.

[0074] (3) Experimental results

[0075] After administration, the tension changes of mouse tracheal smooth muscle are shown in Tables 1 and 2. The Chinese herbal extract can significantly inhibit the abnormal contraction of ASM induced by ACh and high K+ in a dose-dependent manner (see Table 1). Figure 1 and 3 The extract concentrations (IC 50 and IC 75) at which the ASM contraction caused by ACh was inhibited by 50% and 75% were 11.34±0.2928mg / mL and 16.97±0.3238mg / mL, respectively (as shown in Figure 2 below), while the extract concentrations (IC 50 and IC 75) at which the ASM contraction caused by high K+ was inhibited by 50% and 75% were 9.080±0.4370mg / mL and 14.92±1.481mg / mL, respectively (as shown in Figure 4 below).

[0076] Through the in vitro trachea experiment, it can be seen that the drug of the present invention can effectively inhibit the contraction induced by acetylcholine and high potassium stimulation, has the effect of relaxing tracheal smooth muscle, and can effectively relieve the symptoms of airway spasm and airway obstruction. It can be seen that the Chinese medicine composition exerts its efficacy through the mechanism of inhibiting the contraction of bronchial smooth muscle.

[0077] Table 1 Changes in tracheal smooth muscle tension in mice

[0078]

[0079] Table 2 Changes in tracheal smooth muscle tension in mice

[0080]

[0081]

[0082] Test Example 2 Clinical Trial 1

[0083] (1) General Information

[0084] Outpatients from October 2021 to February 2022 were collected, and a self-controlled before-after study design was adopted. A total of 5 asthma patients were included, and 5 cases were completed. The average age was (58.40±13.99) years old, 1 male (20%), 4 females (80%), and the average disease course was (20.80±18.78) years. All were mild to moderate asthma patients.

[0085] (2) Inclusion criteria

[0086] ①18 years old ≤ age < 60 years old, regardless of gender;

[0087] ② Meet the diagnostic criteria for allergic asthma, in the chronic persistent stage, with severity graded as mild to moderate persistent;

[0088] ③ Asthma Control Test (ACT) score ≤ 19 points, indicating that asthma is not controlled;

[0089] ④ Chinese medicine diagnosis is Qi deficiency and dampness obstruction syndrome;

[0090] ⑤The patient signed the informed consent form for this study.

[0091] (3) Exclusion criteria

[0092] ① Patients with severe asthma;

[0093] ② Patients who have experienced acute severe or critical asthma within the past month;

[0094] ③Combined with respiratory diseases such as chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, active pulmonary tuberculosis, etc.;

[0095] ④ Accompanied by severe or uncontrollable underlying diseases: such as liver dysfunction (ALT or AST ≥ 3ULN, total bilirubin ≥ 1.5ULN), renal dysfunction (serum creatinine > 177 μmol / L or 2 mg / dL), chronic congestive heart failure (NYHA III-IV heart function); immunodeficiency, such as malignant tumors, organ or bone marrow transplantation, HIV infection, or taking immunosuppressants in the past 3 months;

[0096] ⑤ Those who are unwilling to accept observation measures or cannot cooperate due to mental illness;

[0097] ⑥ Those who cannot cooperate in completing lung function tests;

[0098] ⑦ Allergic to the drugs contained in the treatment plan;

[0099] ⑧Pregnant, planning pregnancy and breastfeeding patients;

[0100] ⑨ Patients who have received or are currently receiving allergen-specific immunotherapy or anti-IgE therapy;

[0101] ⑩ Patients who are currently participating in or are planning to participate in other clinical trials during the study.

[0102] (4) Treatment plan

[0103] The Chinese medicine composition of Example 1 is taken alone, 1 dose (equivalent to 116 g of crude drug) per day, decocted and taken twice a day in the morning and evening.

[0104] (5) Research cycle

[0105] Treatment for one month.

[0106] (6) Observation indicators and time points

[0107] ① Asthma Quality of Life Questionnaire (AQLQ, such as Figure 6 and 7 ) ; ② Asthma Control Questionnaire (ACQ, such as Figure 8 and 9 );③《Chinese Medicine Dampness Syndrome Assessment Scale, such as Fig.11 》.

[0108] Index ①② was evaluated once before treatment, 2 weeks after treatment, and 4 weeks after treatment, respectively; Index ③ was evaluated once before treatment and 4 weeks after treatment.

[0109] (7) Statistical methods

[0110] Measurement data were described by mean ± standard deviation, and count data were described by rate or percentage. All variables were tested for normality. The paired sample t test was used to compare the measurement data that met the normal distribution before and after treatment, and the Wilcoxon signed rank test was used for the data that did not meet the normal distribution. The chi-square test or Fisher's exact probability method was used to compare the count data before and after treatment. P < 0.05 was considered statistically significant.

[0111] (8) Test results

[0112] ① Comparison of AQLQ scores at each visit point

[0113] The differences in AQLQ scores before and after treatment with Hanxiaofang alone at each visit point were compared and analyzed. The results showed that there was no significant difference in the AQLQ score of V2 after treatment compared with that before treatment (P>0.05); there was a significant difference in the AQLQ score of V3 after treatment compared with that before treatment (P<0.05).

[0114] Table 3 Comparison of AQLQ scores at each visit point

[0115]

[0116] Note: The results of normality test at each visit point were all P>0.05, satisfying normal distribution. The results of variance homogeneity test were P>0.05, satisfying variance homogeneity. The comparison of AQLQ scores at each visit point was performed using grouped F test; the paired t test was used to compare the AQLQ scores of V2, V3 and V1, respectively.

[0117] ② Comparison of ACQ scores at each visit point

[0118] The differences in ACQ scores before and after treatment with Hanxiao Decoction alone at each visit point were compared and analyzed. The results showed that there was no significant difference in the ACQ score of V2 after treatment compared with that before treatment (P>0.05); there was a significant difference in the ACQ score of V3 after treatment compared with that before treatment (P<0.05).

[0119] Table 4 Comparison of ACQ scores at each visit point

[0120]

[0121] Note: The results of normality test at each visit point were all P>0.05, satisfying normal distribution, and the results of variance homogeneity test were P>0.05, satisfying variance homogeneity. The ACQ scores at each visit point were compared using the grouped F test; the ACQ scores of V2, V3 and V1 were compared using the paired t test.

[0122] ③Comparison of patients' dampness syndrome scores before and after treatment

[0123] A comparative analysis of the differences in dampness syndrome scores before and after treatment in patients treated with Hanxiao prescription alone showed that the difference in dampness syndrome scores before and after treatment was statistically significant (P<0.05).

[0124] Table 5 Comparison of dampness syndrome scores of patients before and after treatment

[0125]

[0126] Note: The results of normality test before and after treatment were all P>0.05, satisfying normal distribution. The results of variance homogeneity test were P>0.05, satisfying variance homogeneity. Paired t-test was used to compare dampness syndrome scores.

[0127] The test results show that the use of the drug of the present invention alone to treat asthma patients using pure traditional Chinese medicine can improve the quality of life of patients to a certain extent, and has the potential advantage of improving the level of asthma control. The main symptoms of patients such as wheezing, coughing, chest tightness, and wheezing are significantly improved, and the drug of the present invention can effectively improve the wet constitution of patients, thereby benefiting asthma patients.

[0128] Test Example 3 Clinical Trial 2

[0129] (1) General Information

[0130] Outpatients from October 2021 to February 2022 were collected. A self-controlled before-after study design was adopted. A total of 21 asthma patients were included, 18 of whom completed the case and 3 dropped out. The average age was (49.90±17.62) years old, 7 males (33.33%), 14 females (66.67%), and the average disease course was (8.48±11.41) years. All patients had mild to moderate asthma, and 70% of the patients used budesonide formoterol routinely.

[0131] (2) Inclusion criteria

[0132] ①18 years old ≤ age < 60 years old, regardless of gender;

[0133] ② Meet the diagnostic criteria for allergic asthma, in the chronic persistent stage, with severity graded as mild to moderate persistent;

[0134] ③ Asthma Control Test (ACT) score ≤ 19 points, indicating that asthma is not controlled;

[0135] ④ Chinese medicine diagnosis is Qi deficiency and dampness obstruction syndrome;

[0136] ⑤The patient signed the informed consent form for this study.

[0137] (3) Exclusion criteria

[0138] ① Patients with severe asthma;

[0139] ② Patients who have experienced acute severe or critical asthma within the past month;

[0140] ③Combined with respiratory diseases such as chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, active pulmonary tuberculosis, etc.;

[0141] ④ Accompanied by severe or uncontrollable underlying diseases: such as liver dysfunction (ALT or AST ≥ 3ULN, total bilirubin ≥ 1.5ULN), renal dysfunction (serum creatinine > 177 μmol / L or 2 mg / dL), chronic congestive heart failure (NYHA III-IV heart function); immunodeficiency, such as malignant tumors, organ or bone marrow transplantation, HIV infection, or taking immunosuppressants in the past 3 months;

[0142] ⑤ Those who are unwilling to accept observation measures or cannot cooperate due to mental illness;

[0143] ⑥ Those who cannot cooperate in completing lung function tests;

[0144] ⑦ Allergic to the drugs contained in the treatment plan;

[0145] ⑧Pregnant, planning pregnancy and breastfeeding patients;

[0146] ⑨ Patients who have received or are currently receiving allergen-specific immunotherapy or anti-IgE therapy;

[0147] ⑩ Patients who are currently participating in or are planning to participate in other clinical trials during the study.

[0148] (4) Treatment plan

[0149] On the basis of allowing to continue conventional western medicine treatment, the Chinese medicine composition of Example 1 above is additionally used, one dose per day (equivalent to 116 g of crude drug), decocted and taken twice a day in the morning and evening.

[0150] (5) Research cycle

[0151] Treatment for one month.

[0152] (6) Observation indicators and time points

[0153] ① Asthma Control Test (ACT, such as Figure 5 ) score; ② Asthma Quality of Life Questionnaire (AQLQ, such as Figure 6 and 7 ); ③ Asthma Control Questionnaire (ACQ, such as Figure 8 and 9 ); ④ Adult Asthma Control Assessment Questionnaire (ATAQ, such as Fig.10 ) ; ⑤ Peak expiratory flow (PEF) value; ⑥ TCM dampness syndrome assessment scale, such as Fig.11 》.

[0154] Indexes ①②③④⑤ were evaluated before treatment, 2 weeks after treatment, and 4 weeks after treatment, respectively; index ⑥ was evaluated before treatment and 4 weeks after treatment.

[0155] (7) Statistical methods

[0156] Measurement data were described by mean ± standard deviation, and count data were described by rate or percentage. All variables were tested for normality. The paired sample t test was used to compare the measurement data that met the normal distribution before and after treatment, and the Wilcoxon signed rank test was used for the data that did not meet the normal distribution. The chi-square test or Fisher's exact probability method was used to compare the count data before and after treatment. P < 0.05 was considered statistically significant.

[0157] (8) Test results

[0158] ① Comparison of ACT scores before and after treatment

[0159] Table 6 Comparison of ACT scores before and after treatment

[0160]

[0161] As shown in Table 6, the ACT scores at two weeks and four weeks after the use of the drug of the present invention were significantly improved compared with those before treatment, and the difference was statistically significant (P<0.001), indicating that the drug of the present invention can alleviate asthma symptoms such as wheezing, coughing, dyspnea, chest tightness, etc., reduce the number of attacks, and improve the level of asthma control.

[0162] ②Comparison of AQLQ scores before and after treatment

[0163] Table 7 Comparison of AQLQ scores before and after treatment

[0164]

[0165] As can be seen from Table 7, two weeks and four weeks after the use of the drug of the present invention, AQLQ was improved compared with that before treatment, and the difference was statistically significant (P<0.001), indicating that the drug of the present invention is beneficial to improving symptoms and signs such as fatigue, chest tightness, shortness of breath, irritability and shortness of breath, wheezing, etc., and improves the quality of life of patients.

[0166] ③ Comparison of ACQ scores before and after treatment

[0167] Table 8 Comparison of ACQ scores before and after treatment

[0168]

[0169] As shown in Table 8, the ACQ at two weeks and four weeks after the use of the drug of the present invention was improved compared with that before treatment, and the difference was statistically significant (P<0.001), indicating that the drug of the present invention can alleviate symptoms such as wheezing and dyspnea, reduce the frequency of using bronchodilators, and improve the level of asthma control.

[0170] ④Comparison of ATAQ scores before and after treatment

[0171] Table 9 Comparison of ATAQ scores before and after treatment

[0172]

[0173]

[0174] Note: Wilcoxon signed-rank test was used for before-after comparison

[0175] As shown in Table 9, the ATAQ at two weeks and four weeks after the use of the drug of the present invention was improved compared with that before treatment, and the difference was statistically significant (P < 0.01), indicating that the drug of the present invention improved the degree of asthma control.

[0176] ⑤Comparison of PEF values ​​before and after treatment

[0177] Table 10 Comparison of PEF values ​​before and after treatment

[0178]

[0179] As can be seen from Table 10, after using the drug of the present invention for four weeks, the difference in PEF value is statistically significant, indicating that the drug of the present invention can effectively improve the patient's lung function to a certain extent.

[0180] ⑥ Comparison of TCM dampness syndrome scores before and after treatment

[0181] Table 11 Comparison of TCM dampness syndrome assessment scale before and after treatment

[0182]

[0183] Note: Wilcoxon signed-rank test was used for before-after comparison

[0184] As shown in Table 11, four weeks after the use of the drug of the present invention, the score of dampness syndrome in traditional Chinese medicine was improved compared with that before treatment, and the difference was statistically significant (P<0.01), indicating that the drug of the present invention can effectively improve the dampness syndrome symptoms such as heaviness of limbs, poor appetite, nausea, loose stools and diarrhea in patients.

[0185] In summary, the medicine of the present invention can improve the level of asthma control, improve the quality of life of patients, and to a certain extent improve lung function and alleviate the symptoms of dampness syndrome. The application of this Chinese medicine composition to treat asthma patients has a good therapeutic effect.

[0186] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present application, rather than to limit them; although the present application is described in detail with reference to the above embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the above embodiments, or replace some or all of the technical features therein by equivalents; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present application, and they should all be included in the scope of the claims and specification of the present application. The present application is not limited to the specific embodiments disclosed herein, but includes all technical solutions that fall within the scope of the claims.

Claims

1. A Chinese medicine composition, characterized in that: The invention comprises the following raw materials: ephedra, morinda officinalis, astragalus, atractylodes, dried ginger, asarum, schisandra chinensis, pinellia, belamcanda, siler, and licorice.

2. The Chinese medicine composition according to claim 1, characterized in that The Chinese medicine composition comprises the following raw materials in parts by weight: 6-12 parts of ephedra, 7-13 parts of Morinda officinalis, 27-33 parts of astragalus, 7-13 parts of atractylodes, 5-11 parts of dried ginger, 1-7 parts of asarum, 5-11 parts of schisandra, 7-13 parts of pinellia, 9-15 parts of belamcanda, 7-13 parts of siler, and 2-8 parts of liquorice.

3. The Chinese medicine composition according to claim 2, characterized in that: The Chinese medicine composition comprises the following raw materials in parts by weight: 6-9 parts of ephedra, 10-13 parts of Morinda officinalis, 27-30 parts of astragalus, 10-13 parts of atractylodes, 5-8 parts of dried ginger, 4-7 parts of asarum, 5-8 parts of schisandra, 10-13 parts of pinellia, 9-12 parts of belamcanda, 10-13 parts of siler, and 2-5 parts of liquorice.

4. The Chinese medicine composition according to claim 3, characterized in that: The Chinese medicine composition comprises the following raw materials in parts by weight: 9 parts of ephedra, 10 parts of Morinda officinalis, 30 parts of astragalus, 10 parts of atractylodes, 8 parts of dried ginger, 4 parts of asarum, 8 parts of schisandra, 10 parts of pinellia, 12 parts of belamcanda, 10 parts of siler, and 5 parts of liquorice.

5. The Chinese medicine composition according to any one of claims 1 to 4, characterized in that: The ephedra is honey ephedra, and / or the Morinda officinalis is salt Morinda officinalis, and / or the Schisandra chinensis is steamed Schisandra chinensis, and / or the Pinellia ternata is French Pinellia ternata, and / or the Licorice is roasted Licorice.

6. The preparation of the Chinese medicine composition according to any one of claims 1 to 5, characterized in that: The preparation is an oral preparation, which includes syrup, extract, tablet, mixture, capsule, granule and oral liquid.

7. Use of the Chinese medicine composition according to any one of claims 1 to 5 or the preparation according to claim 6 in the preparation of a drug for inhibiting bronchial smooth muscle contraction.

8. Use of the Chinese medicine composition according to any one of claims 1 to 5 or the preparation according to claim 6 in the preparation of a drug for treating bronchial asthma.

9. The use according to claim 8, characterized in that The bronchial asthma is of the Qi deficiency and dampness obstruction type.

Citation Information

Patent Citations

  • Oral liquid for treating cough and asthma of capillary bronchitis

    CN102327595A

  • Traditional Chinese medicine for treating bronchial asthma and preparation method thereof

    CN103638241A

  • Traditional Chinese medicine composition for treating asthma, preparation method and application thereof

    CN114010710A